A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Hexane () or n-hexane is an organic compound, a straight-chain alkane with six carbon atoms and the molecular formula C6H14. Hexane is a colorless liquid, odorless when pure, and with a boiling point of approximately 69 °C (156 °F). It is widely used as a cheap, relatively safe, largely unreactive, and easily evaporated non-polar solvent, and modern gasoline blends contain about 3% hexane. The term hexanes refers to a mixture, composed largely (>60%) of n-hexane, with varying amounts of the isomeric compounds 2-methylpentane and 3-methylpentane, and possibly, smaller amounts of nonisomeric C5, C6, and C7 (cyclo)alkanes. These "hexanes" mixtures are cheaper than pure hexane, and are often used in large-scale operations that don't require a single isomer (e.g., as cleaning solvent or for chromatography).
Arterial embalming, which involves the injection of embalming chemicals into the blood vessels, usually via the right common carotid artery. Blood and interstitial fluids are displaced by this injection and, along with excess arterial solution, are expelled from the right jugular vein and collectively referred to as drainage. The embalming solution is injected with a centrifugal pump, and the embalmer massages the body to break up circulatory clots so as to ensure the proper distribution of the embalming solution. This process of raising vessels with injection and drainage from a solitary location is known as a single-point injection. In cases of poor circulation of the arterial solution, additional injection points (commonly the axillary, brachial, or femoral arteries, with the ulnar, radial, and tibial vessels if necessary) are used. Cases where more than one vessel is raised are referred to as multi-point injection, with a reference to the number of vessels raised (i.e. a six-point injection or six-pointer). As a general rule, the more points needing to be raised, the greater the difficulty of the case. In some cases draining from a different site from injection (i.e. injecting arterial fluid into the right common carotid artery and draining from the right femoral vein) is referred to as a split (or sometimes cut) injection. In certain cases the embalmer may deem it necessary to perform a restricted cervical injection, which involves injecting the head of the deceased separately from the rest of body.
Like other fast-food chains, In-N-Out uses roadside billboards that direct customers to the nearest location. Billboard ads display an image of the trademarked Double-Double burger. The chain uses short radio commercials, often limited to the song "In-N-Out, In-N-Out. That's what a hamburger's all about." Television commercials, which are less common, feature the hamburger's visual appeal. In-N-Out seldom uses celebrities in ads, although John Cleese and John Goodman have voiced radio spots. In the past, the Snyders also sponsored Christmas music programming with voice-overs expressing the meaning of the holiday. In addition to commercials, In-N-Out benefits from enthusiastic fans who talk to each other. For many years, it has given customers free bumper stickers, which simply say "In-N-Out Burger" but are commonly modified to say "In-N-Out urge". The company helps devoted customers advertise its brand by selling souvenir clothing with the In-N-Out logo. Celebrity fans and free endorsements in mass media also promote the business. When Heisman Trophy winner and Ohio State quarterback Troy Smith raved about In-N-Out cheeseburgers during a press conference before the 2007 BCS National Championship Game, a senior executive said: "It does not get much better than that for us. We're kind of a small company, and we do not have any celebrity endorsers. But I think we just got the best one we could have." Huell Howser was allowed, in what is believed to be a first, to film with his television cameras inside a store for a California's Gold Special.
Sources: en.wikipedia.org
Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. In clinical practice it is used to diagnose and manage cancer treatment, in cardiology and cardiac surgery, and in neurology and psychiatry. PET is a common imaging technique, a medical scintillography technique used in nuclear medicine. A radiopharmaceutical—a radioisotope attached to a drug—is injected into the body as a tracer. When the radiopharmaceutical undergoes beta plus decay, a positron is emitted, and when the positron interacts with an ordinary electron, the two particles annihilate and two gamma rays are emitted in opposite directions. These gamma rays are detected by two gamma cameras to form a three-dimensional image. PET scanners can incorporate a computed tomography scanner (CT) and are known as PET–CT scanners. PET scan images can be reconstructed using a CT scan performed using one scanner during the same session. One of the disadvantages of a PET scanner is its high initial cost and ongoing operating costs.
On 20 May 2021, in an interview with French magazine Paris Match, Lula confirmed that he was a pre-candidate for the next year's elections. The Workers' Party national committee, on 13 April 2022, approved the nomination of former Governor of São Paulo Geraldo Alckmin (PSB) for vice president. The ticket was officialized on 7 May, in a coalition formed by the Brazil of Hope Federation (formed by Workers' Party, Communist Party of Brazil and Green Party), Brazilian Socialist Party, Solidarity and PSOL REDE Federation. With the withdrawal of André Janones on 4 August, the ticket received official support of Avante and Agir. The campaign was marked by polarization and Manichaeism, in which Lula's campaign tried to characterize him as the only alternative in the second round for those who believed in democracy and human rights, while Bolsonaro sought to associate Lula with communism/socialism and far-left anti-democratic regimes such as Venezuela, Cuba, Bolivia, and Nicaragua. The new government would face a fairly conservative Congress, with many of Bolsonaro's ministers and figures close to Bolsonarism occupying seats in parliament. On 2 October, the day of the first round, Lula placed first with 48.43% of the valid votes, leading to a runoff with Jair Bolsonaro, who garnered 43.20% of the valid votes. Lula was elected in the second round, on 30 October, being the first President of Brazil elect for three terms and the first since Getúlio Vargas to be elected for a non-consecutive term.
=== Non-enzymatic additions in vitro === biotinylation: covalent attachment of a biotin moiety using a biotinylation reagent, typically for the purpose of labeling a protein. carbamylation: the addition of isocyanic acid to a protein's N-terminus or the side-chain of Lys or Cys residues, typically resulting from exposure to urea solutions. oxidation: addition of one or more oxygen atoms to a susceptible side-chain, principally of Met, Trp, His or Cys residues. Formation of disulfide bonds between Cys residues. pegylation: covalent attachment of polyethylene glycol (PEG) using a pegylation reagent, typically to the N-terminus or the side-chains of Lys residues. Pegylation is used to improve the efficacy of protein pharmaceuticals.
Muscimol, also known as agarin, pantherine, or pyroibotenic acid, is a GABAA receptor agonist with sedative and hallucinogenic effects and the principal psychoactive constituent of Amanita mushrooms such as Amanita muscaria (fly agaric) and Amanita pantherina (panther cap). It is a 3-hydroxyisoxazole alkaloid and is closely related structurally to the neurotransmitter γ-aminobutyric acid (GABA). The compound is widely used as a ligand and agonist of the GABAA receptor in scientific research. Muscimol is typically taken orally, but may also be smoked. Peak effects occur after 1 to 3 hours orally and its duration is 4 to 10 hours but up to 24 hours. The effects of muscimol in humans include central depression, sedation, sleep, cognitive and motor impairment, hallucinations, perceptual distortion, and muscle twitching, among others. Muscimol acts as a potent GABAA receptor full agonist. However, it acts as a preferential supra-maximal agonist at extrasynaptic δ subunit-containing GABAA receptors. It is also a potent GABAA-ρ receptor partial agonist and a weak GABA reuptake inhibitor. The drug is inactive at the GABAB receptor but is a substrate of GABA transaminase (GABA-T). Muscimol mostly exerts its effects via GABAA receptor activation. It is very different from drugs like benzodiazepines and barbiturates as it is an orthosteric agonist of the GABAA receptor rather than an allosteric modulator. Unlike GABA, muscimol crosses the blood–brain barrier and hence is centrally active. Muscimol is a conformationally restrained analogue of GABA.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.